Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Stock Information for Compugen Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compugen Ltd.

Compugen Reports Third Quarter 2025 Results
Compugen to Participate in Stifel 2025 Healthcare Conference
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen to Present at SITC 2025
Compugen to Present Research at the Single Cell Genomics 2025 Conference
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Compugen Reports Second Quarter 2025 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.